Key result
MDR-TB (OR 2.485), pulmonary TB (OR 1.452), and empyema (OR 4.355) were significant risk factors for treatment delay ≥30 days in patients with pleural tuberculosis.
Population
723 consecutive confirmed TB patients with pleural effusion
Design
Cohort
Authors
Loading...
May warrant closer monitoring to mitigate delays in pleural TB; hypothesis-generating for interventional trials.
Observational (n=723)
Odds Ratio: 2.485 (95% CI 1.347–4.587)
MDR-TB, pulmonary TB, and empyema are significant risk factors for treatment delay in patients with pleural tuberculosis.
Zhang et al. (2018) conducted an observational in Pleural tuberculosis (n=723). MDR-TB, pulmonary TB, and empyema was evaluated on Treatment delay ≥30 days (OR 2.485, 95% CI 1.347-4.587). MDR-TB (OR 2.485), pulmonary TB (OR 1.452), and empyema (OR 4.355) were significant risk factors for treatment delay ≥30 days in patients with pleural tuberculosis.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: